Canada markets closed

Pasithea Therapeutics Corp. (KTTAW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4105-0.1290 (-23.91%)
At close: 03:59PM EST
0.4699 +0.06 (+14.47%)
After hours: 05:30PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5395
Open0.5000
Bid0.4105 x 900
Ask0.4660 x 800
Day's Range0.4101 - 0.5000
52 Week Range0.4101 - 0.5000
Volume127,382
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

    -- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals -- -- Expansion to additional U.S. cities in coming months -- MIAMI BEACH, Fla., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today anno

  • GlobeNewswire

    Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

    MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules. The Company sold an aggregate of 8.68 million shares of common stock an

  • GlobeNewswire

    Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

    MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, a